Pharmaceutical Computer Systems Validation: Quality, Assurance, Risk Management and Regulatory Compliance
点此进入淘宝搜索页搜索分類: 图书,进口原版,Medicine（医学）,Pharmacology（药理学）,Pharmacy,
品牌: Guy Wingate
基本信息出版社:Informa Healthcare; Revised精装:765页正文语种:英语ISBN:1420088947条形码:9781420088946商品尺寸:25.4 x 18.3 x 4.8 cmASIN:1420088947商品描述Thoroughly revised to include the latest industry developments, the Second Edition presents a comprehensive overview of computer validation and verification principles and how to put them into practice. To provide the current best practice and guidance on identifying and implementing improvements for computer systems, the text extensively reviews regulations of pharmaceuticals, healthcare products, blood processing, medical devices, clinical systems, and biotechnology. Ensuring that organizations transition smoothly to the new system, this guide explains how to implement the new GMP paradigm while maintaining continuity with current practices. In addition, all 24 case studies from the previous edition have been revised to reflect the new system. Key topics in Pharmaceutical Computer Systems Validation, Second Edition include: ULLIGAMP5, ASTM 2500, EU GMP (Annex 11), and US GMP revisions to regulatory requirements for electronic records and signatures that should be published in 2008/LILIICH Guidance Q8, Q9, and Q10 expectations/LILIFDA cGMPs for the 21st Century Initiative and associated guidance/LILIPIC/S Guidance on Good Practice for Computerized Systems in GxP Environments/LILIWK9864 Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment/LILIthe indirect developments from FDA/EU/Japan regulators and industry/LILIthe role of QA department, and internal and external suppliers/LILIthe integration of computer systems validation into single overall approach for wider system/LILIpractical guidance on handling common high, medium, and low risk issues that can occur during the life cycle of a computer system/LILImanaging outsource partners and handling legacy systems/LILItopical issues uncovered by regulatory authorities including US FDA/LI/UL